Miller, Robert E <br/><br/>
RANKL inhibition blocks osteolytic lesions and reduces skeletal tumor burden in models of non-small-cell lung cancer bone metastases.  [electronic resource] 

 -  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer  Mar 2014 
 - 345-54 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1556-1380 
<br/><br/><label>Standard No.: </label>10.1097/JTO.0000000000000070  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Anticoagulants--pharmacology<br/>Bone Neoplasms--metabolism<br/>Carcinoma, Non-Small-Cell Lung--metabolism<br/>Enoxaparin--pharmacology<br/>Female<br/>Humans<br/>Lung Neoplasms--metabolism<br/>Mice<br/>Mice, Nude<br/>Osteolysis--drug therapy<br/>Osteoprotegerin--immunology<br/>RANK Ligand--antagonists & inhibitors<br/>Survival Rate<br/>Tumor Burden<br/>Tumor Cells, Cultured